Analysts' Actions: American Eagle, Boulder Brands, HealthStream, Carrizo

NEW YORK (TheStreet) -- RATINGS CHANGES

American Eagle Outfitters (AEO) was downgraded to equal weight from overweight at Barclays. The 12-month price target was lowered to $11 from $15, as the U.S. Retail Softline group changed to a negative outlook from positive, Barclays said. American Eagle is trading at a much richer valuation than other specialty retailers, making downside risk heightened.

Agios Pharmaceuticals (AGIO) was downgraded to neutral from buy at Goldman Sachs. Shares have reached the 12-month price target and the market is adequately capturing the potential opportunities given the company's stage of development, said Goldman. The pipeline remains promising.

Watch the video below for more analysts' actions:

Akorn (AKRX) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: AKRX Ratings Report.

Abercrombie & Fitch (ANF) was downgraded to perform from outperform at Oppenheimer. The price target was lowered to $30 from $50 on lack of visibility regarding brand turnaround and mounting uncertainty around international sales, said Oppenheimer. These issues make near-term projections less clear.

Boulder Brands (BDBD) was upgraded to overweight from neutral at Piper Jaffray. Potentially lower commodity costs and reduced expectations have created an attractive risk/reward situation at current levels, said Piper Jaffray.

Carrizo Oil and Gas (CRZO) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: CRZO Ratings Report.

Dominion Midstream Partners (DM) was initiated at Goldman Sachs with a neutral rating. The company should see strong distribution growth, said Goldman. However, that growth is largely priced in to current valuation.

Eaton Vance (EV) was downgraded to underweight from neutral at J.P. Morgan. A surge in share price following the announcement of SEC exemptive relief implies optimistic expectations for new exchange-traded managed funds, said J.P. Morgan.

HealthStream (HSTM) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: HSTM Ratings Report.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes", which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

3 Things We Just Learned About Chip Stocks -- and It's Not All Bad News

3 Things We Just Learned About Chip Stocks -- and It's Not All Bad News

Chipotle's New CEO Has Set its Path for Redemption

Chipotle's New CEO Has Set its Path for Redemption